LARIMAR THERAPEUTICS INC
LRMRNASDAQ🏆 #3371 by market capEarnings Nov 5 · PostUS Equity
$2.70▲ $0.15 (+5.88%)
Latest quoteTrack LRMR
Get earnings, price moves & breaking news on Telegram
24h▲ 5.9%
7d—
14d—
30d—
ytd—
1y—
🏦Market Cap
$280M
Small Cap
📈Revenue Growth (YoY)
0.0%
Slowing
📊Gross Margin
0.0%
Thin
💵FCF Margin
0.0%
Thin
⚖️P/S Ratio
0.0x
Cheap
Otter Score
56
Fair
No chart data available for LRMR.
Trading Snapshot
- Day Range
- $2.56 – $2.73
- 52-Week Range
- $1.92 – $6.42
- Volume (shares)
- 78,387
- Avg Volume (shares)
- —
- Shares Outstanding
- 103.9M
- Next Earnings
- 2026-11-05
Fundamentals Snapshot
- Annual Revenue
- —
- Last Q Revenue
- —
- P/E Ratio
- -1.3
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-1.66
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +33.5%
LARIMAR THERAPEUTICS INC
LRMRFinancial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$172M▲ +89.8% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$113M▲ +59.0% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
85.2M▲ +33.5% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$81M▲ +$53M YoY
StockOtter · stockotter.spaceAbout LARIMAR THERAPEUTICS INC
Headquartered in Bala Cynwyd, Pennsylvania, Larimar Therapeutics, Inc. operates as a clinical-stage biotechnology firm. Its core mission involves crafting therapies for rare diseases, leveraging a distinctive cell-penetrating peptide technology platform. The company's foremost experimental therapy, CTI-1601, is presently undergoing Phase 1 clinical trials. This drug candidate is being developed to combat Friedreich's ataxia, a genetic illness that is rare, relentlessly progressive, and ultimately fatal.
🦦
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
56/100
Analyst data unavailable.
Latest News & Updates
News unavailable.